Clinical meaning
Carcinoid syndrome is a clinical constellation of symptoms caused by the systemic release of vasoactive substances -- primarily serotonin (5-hydroxytryptamine/5-HT), histamine, kallikrein, prostaglandins, and tachykinins -- from neuroendocrine tumors (NETs, formerly called carcinoid tumors). Neuroendocrine tumors arise from enterochromaffin cells, which are part of the diffuse neuroendocrine system scattered throughout the gastrointestinal tract, bronchopulmonary system, and other organs. These cells normally produce and store serotonin and other bioactive amines in dense-core secretory granules. Serotonin synthesis begins with the essential amino acid tryptophan, which is hydroxylated by tryptophan hydroxylase to 5-hydroxytryptophan (5-HTP), then decarboxylated by aromatic L-amino acid decarboxylase (AADC) to serotonin (5-HT). In patients with large tumor burdens, carcinoid tumors can consume up to 60% of dietary tryptophan for serotonin synthesis, potentially causing tryptophan deficiency. Since tryptophan is also the precursor for niacin (vitamin B3) synthesis, tryptophan depletion can produce pellagra (the 4 Ds: dermatitis, diarrhea, dementia, and if untreated, death) -- this is an important but often overlooked complication of advanced carcinoid syndrome. A critical concept for understanding why carcinoid syndrome typically requires hepatic metastases is first-pass hepatic metabolism. Midgut carcinoid tumors (the most common type, arising in the ileum and appendix) drain via the portal venous system directly into the liver. When the tumor is confined to the GI tract without liver metastases, serotonin and other vasoactive substances released into the portal blood are efficiently metabolized by hepatic monoamine oxidase (MAO) and aldehyde dehydrogenase, converting serotonin to its inactive metabolite 5-hydroxyindoleacetic acid (5-HIAA) before it can reach the systemic circulation. Therefore, carcinoid syndrome rarely occurs with primary midgut tumors unless hepatic metastases are present (which bypass first-pass metabolism by releasing serotonin directly into the hepatic veins and systemic circulation) or unless the tumor drains outside the portal system. Exceptions include bronchial and ovarian carcinoid tumors, which drain directly into the systemic venous circulation (not through the portal system) and can cause carcinoid syndrome without liver metastases. The systemic effects of carcinoid syndrome are mediated by the tumor's secretory products acting on specific receptors throughout the body. Serotonin acting on 5-HT receptors in the intestinal wall stimulates intestinal motility and secretion, causing the secretory diarrhea that is the most common symptom (occurring in 70-80% of patients). The diarrhea is typically watery, non-bloody, and may be associated with abdominal cramping; it results from both increased motility (5-HT4 receptor stimulation on enteric neurons) and increased fluid and electrolyte secretion (5-HT3 receptor stimulation on enterocytes). Flushing is the second most common symptom (60-85%), caused by release of kallikrein (which generates vasodilatory bradykinin from kininogen), histamine, prostaglandins, and tachykinins (substance P and neurokinin A). Classic midgut carcinoid flushing is typically brief (1-5 minutes), affects the face and upper trunk, and produces a pink-to-red skin color. In contrast, foregut (bronchial, gastric) carcinoid flushing tends to be more prolonged and severe, with a purplish hue (histamine-mediated), and may be associated with lacrimation, rhinorrhea, and bronchospasm. Flushing episodes can be triggered by stress, alcohol, exercise, certain foods (tyramine-containing cheeses, chocolate), and specific medications (catecholamines, beta-blockers if administered without prior alpha-blockade in pheochromocytoma but relevant as flushing triggers in carcinoid). Carcinoid heart disease (Hedinger syndrome) is the most serious complication, occurring in approximately 50-60% of patients with carcinoid syndrome. Serotonin causes fibrotic thickening and retraction of the right-sided heart valves (tricuspid and pulmonary). The mechanism involves serotonin binding to 5-HT2B receptors on valvular interstitial cells, activating TGF-beta signaling pathways that stimulate myofibroblast proliferation, collagen deposition, and fibrous plaque formation on the endocardial surface of the valves. The right-sided predominance occurs because serotonin in the systemic venous blood reaches the right heart first and is then inactivated by monoamine oxidase in the pulmonary vasculature before reaching the left heart. The resulting valvular dysfunction typically causes tricuspid regurgitation (most common) and pulmonary stenosis, leading to right-sided heart failure (peripheral edema, hepatomegaly, ascites, elevated JVP). Left-sided valvular involvement is rare unless there is a patent foramen ovale (allowing serotonin to bypass pulmonary metabolism) or bronchial carcinoid (serotonin enters pulmonary veins directly). Bronchospasm occurs in approximately 10-20% of patients (primarily with foregut carcinoid tumors producing histamine) and can be severe. Standard beta-agonist bronchodilators should be used cautiously because beta-receptor stimulation may paradoxically worsen flushing and hypotension during carcinoid crisis. Carcinoid crisis is a life-threatening complication characterized by severe, prolonged flushing with profound hypotension, bronchospasm, tachycardia, and potentially cardiovascular collapse. It can be triggered by anesthesia, surgery (particularly tumor manipulation), embolization procedures, and catecholamine administration. Prevention and treatment of carcinoid crisis requires IV octreotide. Diagnosis relies on biochemical confirmation: 24-hour urinary 5-HIAA (5-hydroxyindoleacetic acid, the primary serotonin metabolite) is the gold standard biochemical test, with sensitivity of 70-75% and specificity of 95-100%. Plasma chromogranin A (CgA) is a general neuroendocrine tumor marker that correlates with tumor burden. Imaging with CT, MRI, and somatostatin receptor scintigraphy (OctreoScan) or gallium-68 DOTATATE PET/CT (more sensitive) identifies and stages the tumor and its metastases. Treatment combines tumor-directed therapy (surgical resection when feasible, hepatic-directed therapy for liver metastases) with symptom control using somatostatin analogs (octreotide, lanreotide), which are the cornerstone of carcinoid syndrome management.